Mehmet Bozbay1, Huseyin Uyarel2, Sahin Avsar3, Ahmet Oz3, Muhammed Keskin3, Ahmet Murat3, Adnan Kaya3, Halil Atas4, Ahmet Altug Cincin4, Murat Ugur3, Mehmet Eren3. 1. Department of Cardiology, Dr. Siyami Ersek Cardiovascular and Thoracic Surgery Research and Training Hospital, Tıbbiye Caddesi No: 13 Kadikoy, 34668, Istanbul, Turkey. mbozbay42@gmail.com. 2. Department of Cardiology, School of Medicine, Bezm-i Alem Vakif University, Istanbul, Turkey. 3. Department of Cardiology, Dr. Siyami Ersek Cardiovascular and Thoracic Surgery Research and Training Hospital, Tıbbiye Caddesi No: 13 Kadikoy, 34668, Istanbul, Turkey. 4. Department of Cardiology, School of Medicine, Marmara University, Istanbul, Turkey.
Abstract
BACKGROUND: Elevated admission serum glucose level is associated with unfavourable clinical outcomes in various clinical conditions. The aim of this study was to investigate the relationship between admission glucose levels and in-hospital and long-term adverse clinical outcomes in patients with pulmonary embolism (PE) treated with thrombolytic therapy. METHODS: A total of 183 consecutive confirmed acute PE patients (98 female and 85 male; mean age 61.9 ± 15.7 years) who were treated with thrombolytic therapy enrolled in this study. The study population was categorised into four quartiles according to admission serum glucose levels (group I: glucose ≤115 mg/dl; group II: glucose >115-141 mg/dl; group III: glucose >141-195 mg/dl; and group IV: glucose ≥196 mg/dl). RESULTS: In-hospital mortality was significantly higher in group IV (28.8 %) compared to group III (15.2 %), group II (6.6 %), and group I (2.1 %) (p < 0.001). In multivariate analysis, admission glucose level (OR 1.013, 95 % CI 1.004-1.021, p = 0.004) and admission anaemia (OR 0.602, 95 % CI 0.380-0.955, p = 0.03) were independent predictors of in-hospital mortality. The mean follow-up period was 34 months. During long-term follow-up, all-cause mortality, recurrent PE, major and minor bleeding were similar among the four groups. CONCLUSION: Admission glucose level is a simple, inexpensive, easily available, and effective laboratory parameter for predicting in-hospital mortality in patients with PE.
BACKGROUND: Elevated admission serum glucose level is associated with unfavourable clinical outcomes in various clinical conditions. The aim of this study was to investigate the relationship between admission glucose levels and in-hospital and long-term adverse clinical outcomes in patients with pulmonary embolism (PE) treated with thrombolytic therapy. METHODS: A total of 183 consecutive confirmed acute PE patients (98 female and 85 male; mean age 61.9 ± 15.7 years) who were treated with thrombolytic therapy enrolled in this study. The study population was categorised into four quartiles according to admission serum glucose levels (group I: glucose ≤115 mg/dl; group II: glucose >115-141 mg/dl; group III: glucose >141-195 mg/dl; and group IV: glucose ≥196 mg/dl). RESULTS: In-hospital mortality was significantly higher in group IV (28.8 %) compared to group III (15.2 %), group II (6.6 %), and group I (2.1 %) (p < 0.001). In multivariate analysis, admission glucose level (OR 1.013, 95 % CI 1.004-1.021, p = 0.004) and admission anaemia (OR 0.602, 95 % CI 0.380-0.955, p = 0.03) were independent predictors of in-hospital mortality. The mean follow-up period was 34 months. During long-term follow-up, all-cause mortality, recurrent PE, major and minor bleeding were similar among the four groups. CONCLUSION: Admission glucose level is a simple, inexpensive, easily available, and effective laboratory parameter for predicting in-hospital mortality in patients with PE.
Authors: Ana T Timóteo; Ana L Papoila; Pedro Rio; Fernando Miranda; Maria L Ferreira; Rui C Ferreira Journal: Eur Heart J Acute Cardiovasc Care Date: 2014-03-31
Authors: P Petursson; J Herlitz; K Caidahl; S Gudbjörnsdottir; T Karlsson; E Perers; H Sjöland; M Hartford Journal: Int J Cardiol Date: 2006-07-18 Impact factor: 4.164
Authors: B A Lemkes; J Hermanides; J H Devries; F Holleman; J C M Meijers; J B L Hoekstra Journal: J Thromb Haemost Date: 2010-05-12 Impact factor: 5.824
Authors: Boris Mraovic; Brian R Hipszer; Richard H Epstein; Edward C Pequignot; Javad Parvizi; Jeffery I Joseph Journal: J Arthroplasty Date: 2008-12-04 Impact factor: 4.757
Authors: Alexandre Y Poppe; Sumit R Majumdar; Thomas Jeerakathil; William Ghali; Alastair M Buchan; Michael D Hill Journal: Diabetes Care Date: 2009-01-08 Impact factor: 17.152